The impact of genomic changes on treatment of lung cancer.
about
ALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsUpdate in Lung Cancer 2014Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinomaDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerThe evolving genomic classification of lung cancer.Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer.Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in TaiwanMulti-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer.MicroRNA as tools and therapeutics in lung cancerBRAF gene: From human cancers to developmental syndromes.Differentially expressed and activated proteins associated with non small cell lung cancer tissuesLung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma.Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population.Destaining of Diff-Quik stained cytologic smears is not necessary for the detection of anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma by fluorescence in situ hybridizationAn analysis of the relationship between metastases and cachexia in lung cancer patientsMYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.Clinicopathological significance of p14ARF expression in lung cancer: a meta-analysisTreating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.ROS1 gene rearrangement and copy number gain in non-small cell lung cancer.Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients.Preoperative high-intensity training in frail old patients undergoing pulmonary resection for NSCLC.Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.Identification of key differentially expressed genes associated with non‑small cell lung cancer by bioinformatics analyses.
P2860
Q26769879-1C1F694B-F890-4700-B28D-E637D4A61503Q27027385-16F81152-57A6-43F2-9931-4C325870366CQ27853339-F811114F-473C-4409-8D9F-CE3FEF001A56Q28385559-70EC63EE-EEE6-403C-80B5-2F47CD933765Q28388180-FDD3DD8B-1C73-422D-968C-84D8DC1A9235Q30762699-6BEFDB24-1664-4947-8E14-FCFDFB8A388AQ34295621-997F946B-74FB-4AF0-B5C5-E33CA2B1B03CQ34852043-B3DABF38-BB46-42E2-80B7-ED15303F9F9EQ34987026-6005648C-5DB5-41DE-9B19-D8268E91F693Q35196603-8D5FA216-EAAB-489B-96C5-5EE13C780B77Q35541778-FA5B18EE-6A2C-429F-8C01-E32B270B2C09Q35551845-E90ED8B9-CCEA-4563-81C1-66DE9C12C4AAQ35738706-AA5EEA83-C44A-471F-B275-6C556735F304Q35802430-B3FA8879-7466-4CCC-9F59-5BEA7DDE1E0AQ35805319-0DC5779D-04C3-496E-BE77-203A9ED74BB2Q36303134-2C6CB4F7-82BB-49BA-B201-43F84B69A943Q36651307-985402A3-F605-4422-9808-C68559B27C23Q36983665-213B3A19-89A1-41EE-83A7-26137176A6B9Q37199755-AE0005D3-97DF-4101-B2CC-2D9D8E9362CDQ37321143-23D8A846-1FD9-41CC-AC5D-C5A4D9396592Q37718370-A455995F-2097-4A6A-9C9E-97ABD3E3DD25Q38203468-05B3186F-EF64-4D05-BEC6-10418C777DAEQ38731119-4019D94C-5579-4718-9090-5F76DC743BCBQ38784576-72E46114-8733-4DD5-BCD7-9F559F736FC2Q39039088-E3340EB4-2EB6-4D6E-A4C5-863FB1DCB47CQ39102554-66626F92-B133-4EB6-BA21-121F36F6EF39Q39183265-B6121743-CBD5-45C0-8C87-82E023527E75Q47578326-B25B51F3-0205-4E29-8DC6-3590A3DA1077Q50877452-C5F3EAF8-EF30-40C0-B836-813176AE1356Q51832091-415DECFB-6065-4C42-95E3-85A63F664204Q52655141-F674A64D-EB42-4248-BA69-E50EA1BAC39CQ52726915-433FCCF8-A047-47B2-9C09-2D6460AEDEF3
P2860
The impact of genomic changes on treatment of lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The impact of genomic changes on treatment of lung cancer.
@en
The impact of genomic changes on treatment of lung cancer.
@nl
type
label
The impact of genomic changes on treatment of lung cancer.
@en
The impact of genomic changes on treatment of lung cancer.
@nl
prefLabel
The impact of genomic changes on treatment of lung cancer.
@en
The impact of genomic changes on treatment of lung cancer.
@nl
P2860
P1476
The impact of genomic changes on treatment of lung cancer.
@en
P2093
Bruce E Johnson
Stephanie Cardarella
P2860
P304
P356
10.1164/RCCM.201305-0843PP
P407
P577
2013-10-01T00:00:00Z